Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 415

1.

Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.

Slipicevic A, Holm R, Emilsen E, Ree Rosnes AK, Welch DR, Mælandsmo GM, Flørenes VA.

BMC Cancer. 2012 Feb 22;12:73. doi: 10.1186/1471-2407-12-73.

2.

The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells.

Slipicevic A, Jørgensen K, Skrede M, Rosnes AK, Trøen G, Davidson B, Flørenes VA.

BMC Cancer. 2008 Sep 30;8:276. doi: 10.1186/1471-2407-8-276.

3.

Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.

Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8606-14.

4.

Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis.

Li J, Cheng Y, Tai D, Martinka M, Welch DR, Li G.

Oncogene. 2011 Feb 24;30(8):896-906. doi: 10.1038/onc.2010.470. Epub 2010 Oct 11.

5.
6.

Location, location, location: the BRMS1 protein and melanoma progression.

Riker AI, Samant RS.

BMC Med. 2012 Feb 22;10:19. doi: 10.1186/1741-7015-10-19. Review.

7.

A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers.

Frolova N, Edmonds MD, Bodenstine TM, Seitz R, Johnson MR, Feng R, Welch DR, Frost AR.

Tumour Biol. 2009;30(3):148-59. doi: 10.1159/000228908. Epub 2009 Jul 16. Erratum in: Tumour Biol. 2009;30(4):175.

8.

Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand.

Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Screaton G, Hersey P.

Hum Pathol. 2006 Oct;37(10):1286-94. Epub 2006 Jul 18.

PMID:
16949935
9.

Prognostic significance of cytoplasmic p27 expression in human melanoma.

Chen G, Cheng Y, Zhang Z, Martinka M, Li G.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2212-21. doi: 10.1158/1055-9965.EPI-11-0472. Epub 2011 Aug 9.

10.

The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.

Pilloni L, Bianco P, Difelice E, Cabras S, Castellanos ME, Atzori L, Ferreli C, Mulas P, Nemolato S, Faa G.

Eur J Histochem. 2011 Jun 7;55(2):e20. doi: 10.4081/ejh.2011.e20.

11.

CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.

Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A.

J Clin Pathol. 2007 Jun;60(6):596-9. Epub 2006 Mar 7.

12.

High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.

Chin SY, Wu PR, Shih YH, Yeh CM, Lee WR, Shen SC, Yeh KT, Jiang MC, Tseng JT.

Int J Clin Exp Pathol. 2015 Feb 1;8(2):1393-401. eCollection 2015.

13.

Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance.

Nambiar S, Mirmohammadsadegh A, Hassan M, Mota R, Marini A, Alaoui A, Tannapfel A, Hegemann JH, Hengge UR.

Carcinogenesis. 2007 Dec;28(12):2501-10. Epub 2007 Sep 3.

PMID:
17768177
14.

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.

Dai DL, Martinka M, Li G.

J Clin Oncol. 2005 Mar 1;23(7):1473-82.

PMID:
15735123
15.

Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.

Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM, Rimm DL.

Mod Pathol. 2008 Sep;21(9):1121-9. doi: 10.1038/modpathol.2008.100. Epub 2008 Jun 13.

16.

Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.

Flørenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R.

Am J Pathol. 1998 Jul;153(1):305-12.

17.

Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival.

Chen G, Cheng Y, Zhang Z, Martinka M, Li G.

PLoS One. 2011 Feb 28;6(2):e17578. doi: 10.1371/journal.pone.0017578.

18.

Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome.

Slipicevic A, Holm R, Nguyen MT, Bøhler PJ, Davidson B, Flørenes VA.

Am J Clin Pathol. 2005 Oct;124(4):528-36.

PMID:
16146807
19.

Profiling of ABC transporters ABCB5, ABCF2 and nestin-positive stem cells in nevi, in situ and invasive melanoma.

Setia N, Abbas O, Sousa Y, Garb JL, Mahalingam M.

Mod Pathol. 2012 Aug;25(8):1169-75. doi: 10.1038/modpathol.2012.71. Epub 2012 May 4.

20.

WT 1 expression in nevi and melanomas: a marker of melanocytic invasion into the dermis.

Garrido-Ruiz MC, Rodriguez-Pinilla SM, Pérez-Gómez B, Rodriguez-Peralto JL.

J Cutan Pathol. 2010 May;37(5):542-8. doi: 10.1111/j.1600-0560.2009.01379.x. Epub 2009 Jul 22.

PMID:
19638168

Supplemental Content

Support Center